VBI Vaccines Inc. (NASDAQ:VBIV) and its partner Brii Biosciences announced positive interim results from a Phase 2 study of BRII-179 (VBI-2601), a treatment for chronic hepatitis B. The treatment, in combination with PEG-IFNα, showed increased HBsAg loss rate and a significantly increased seroconversion rate. The safety findings were similar to previous reports. In 2023, VBI and Brii Bio expanded their partnership to include an exclusive global license to develop and commercialize BRII-179 and an exclusive license for VBI's prophylactic 3-antigen adult HBV vaccine in the Asia Pacific region, excluding Japan.